In addition to racial inequities in SGLT2 inhibitor use, we discovered other structural inequities based on gender and socioeconomic status that can be addressed intersectionally.41 Among patients with type 2 diabetes, females were less likely to be prescribed an SGLT2 inhibitor, even among those with HFrEF, ASCVD, and CKD. This evidence concerns the gene SLC5A2 and atherosclerosis.